- Provider
- CoreAge Rx
- Advertised starting price
- $79 per month; verify billing term
- FDA-approved finished product?
- No; compounded preparation
- Price basis
- Publisher-supplied correction; confirm selected plan
Identify the preparation, not just the ingredient
CoreAge Rx describes this offering as compounded semaglutide. It is not branded Wegovy and should not be represented as an FDA-approved generic version. The pharmacy, concentration and complete formulation need confirmation for the selected prescription.[source]
Ask why the clinician proposes a compounded preparation and how that choice relates to available approved medicines. A promotional comparison cannot resolve that patient-specific decision.
What the advertised price leaves to confirm
The publisher supplied a corrected starting $79 monthly price and states the price is the same at every dose. Verify how that applies to the selected term, what is billed upfront and which clinical or shipping charges are included.[source]
The help catalog describes multi-month plans and a consultation-fee deduction if prescribing is declined. The full commitment is therefore a more useful comparison than an isolated monthly number.[source]
Do not borrow the branded trial outcome
The semaglutide arm of SURMOUNT-5 used specified doses of a branded weekly injection. It did not test this CoreAge Rx preparation. We do not attach the trial’s mean result to this product or claim that it predicts a particular patient’s experience.[source]
Confirm the label and clinical contact
FDA raises concerns about unapproved GLP-1 products, including dosing errors and semaglutide salt forms. Ask the prescriber and pharmacy to identify the exact preparation and provide understandable instructions.[source]
This review does not calculate syringe units or offer a dose schedule. Questions about a supplied label should go to the pharmacy or clinician, especially if the instructions are unclear.
Use both access categories in the shortlist
Compare this offer with Mochi’s compounded semaglutide on formulation, total cost and care. Compare approved Wegovy routes separately, preserving their different product status. CoreAge Rx’s featured position is commercial and does not erase these distinctions.
Sources & further reading
Provider pages establish what a brand markets. Clinical and regulatory sources establish the limits of the evidence. Each source has its own last-checked date below.
- CoreAge Rx: current advertised treatments and pricesStandard GLP-1 prices use the publisher-supplied correction: semaglutide $79/month from; tirzepatide $129/month from. Other original service details retain their October 8 check date. · Checked October 8, 2026
- CoreAge Rx Help Center: current product catalogProvider formulation and consultation information · Checked October 8, 2026
- Aronne et al., NEJM 2025: tirzepatide compared with semaglutide for obesityPrimary randomized trial abstract; SURMOUNT-5, 751 adults without diabetes, 72 weeks; funded by Eli Lilly · Checked October 8, 2026
- FDA: concerns with unapproved GLP-1 drugsCompounded-product risks, salt forms, dosing errors and online red flags · Checked October 10, 2026